Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-23T06:28:16.340Z Has data issue: false hasContentIssue false

Chapter 6 - Hematopoietic Cell Transplantation: Is There Any Age Limit?

from Section 1 - Recipient Selection for Hematopoietic Cell Transplantation

Published online by Cambridge University Press:  24 May 2017

By
Andrew S. Artz  and
Rebecca L. Olin
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 51 - 58
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Pasquini, M, Wang, Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. 2013.Google Scholar
Artz, A, Ershler, W. Hematopoietic cell transplantation in older adults. In Hurria, A, Cohen, HJ, editors. Practical geriatric oncology. Cambridge, New York: Cambridge University Press; 2010. p. 1 online resource (x, 435 p.).Google Scholar
Ustun, C, Lazarus, HM, Weisdorf, D. To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant. 2013;48(12):1497–505.Google Scholar
Oran, B, Weisdorf, DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–24.Google Scholar
Richa, E, Papari, M, Allen, J, Martinez, G, Wickrema, A, Anastasi, J, et al. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2009;15(11):1394–9.CrossRefGoogle Scholar
Alousi, AM, Le-Rademacher, J, Saliba, RM, Appelbaum, FR, Artz, A, Benjamin, J, et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood. 2013;121(13):2567–73.CrossRefGoogle ScholarPubMed
De Latour, RP, Labopin, M, Cornelissen, J, Vindelov, L, Blaise, D, Milpied, N, et al. Equivalent outcome between older siblings and unrelated donors after reduced intensity allogeneic hematopoietic stem cell transplantation for patients older than 50 years with acute myeloid leukemia in first complete remission: A report from the ALWP of EBMT. Blood 2012;120:Abstract 961.Google Scholar
Sorror, ML, Sandmaier, BM, Storer, BE, Franke, GN, Laport, GG, Chauncey, TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA : The Journal of the American Medical Association. 2011;306(17):1874–83.Google Scholar
Kroger, N, Zabelina, T, de Wreede, L, Berger, J, Alchalby, H, van Biezen, A, et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia. 2013;27(3):604–9.Google Scholar
Peffault de Latour, R, Brunstein, CG, Porcher, R, Chevallier, P, Robin, M, Warlick, E, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2013;19(9):1355–60.Google Scholar
Sorror, ML, Storb, RF, Sandmaier, BM, Maziarz, RT, Pulsipher, MA, Maris, MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014.Google Scholar
Koreth, J, Aldridge, J, Kim, HT, Alyea, EP 3rd, Cutler, C, Armand, P, et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010;16(6):792–800.Google Scholar
Chevallier, P, Szydlo, RM, Blaise, D, Tabrizi, R, Michallet, M, Uzunov, M, et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant. 2012;18(2):289–94.Google Scholar
McClune, BL, Weisdorf, DJ, Pedersen, TL, Tunes da Silva, G, Tallman, MS, Sierra, J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878–87.Google Scholar
Lim, Z, Brand, R, Martino, R, van Biezen, A, Finke, J, Bacigalupo, A, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28(3):405–11.Google Scholar
McClune, BL, Ahn, KW, Wang, HL, Antin, JH, Artz, AS, Cahn, JY, et al. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014;20(7):960−8.Google Scholar
Estey, E, de Lima, M, Tibes, R, Pierce, S, Kantarjian, H, Champlin, R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109(4):1395–400.Google Scholar
Farag, SS, Maharry, K, Zhang, MJ, Perez, WS, George, SL, Mrozek, K, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60–70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011;17(12):1796–803.CrossRefGoogle ScholarPubMed
Kurosawa, S, Yamaguchi, T, Uchida, N, Miyawaki, S, Usuki, K, Watanabe, M, et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant. 2011;17(3):401–11.CrossRefGoogle ScholarPubMed
Devine, S, Owzar, K, Blum, W, DeAngelo, D, Stone, R, Hsu, J, et al. A Phase II study of allogeneic transplantation for older patients with AML in first complete remission using a reduced intensity conditioning regimen: results from CALGB 100103/BMT CTN 0502. Blood. 2012;120:Abstract 230.Google Scholar
Koreth, J, Pidala, J, Perez, WS, Deeg, HJ, Garcia-Manero, G, Malcovati, L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31(21):2662–70.CrossRefGoogle ScholarPubMed
Buchner, T, Berdel, WE, Haferlach, C, Haferlach, T, Schnittger, S, Muller-Tidow, C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27(1):61–9.Google Scholar
Muffly, LS, Kocherginsky, M, Stock, W, Chu, Q, Bishop, MR, Godley, LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99(8):1373–9.Google Scholar
Sorror, ML, Maris, MB, Storb, R, Baron, F, Sandmaier, BM, Maloney, DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.Google Scholar
Sorror, M. Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes. Biol Blood Marrow Transplant. 2009;15(1 Suppl):149–53.Google Scholar
Raimondi, R, Tosetto, A, Oneto, R, Cavazzina, R, Rodeghiero, F, Bacigalupo, A, et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. Blood. 2012;120(6):1327–33.CrossRefGoogle ScholarPubMed
Giles, FJ, Borthakur, G, Ravandi, F, Faderl, S, Verstovsek, S, Thomas, D, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136(4):624–7.Google Scholar
Sperr, WR, Wimazal, F, Kundi, M, Baumgartner, C, Nosslinger, T, Makrai, A, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21(1):114–9.Google Scholar
Hurria, A, Togawa, K, Mohile, SG, Owusu, C, Klepin, HD, Gross, CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.CrossRefGoogle ScholarPubMed
Klepin, HD, Geiger, AM, Tooze, JA, Kritchevsky, SB, Williamson, JD, Pardee, TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013; 121(21):4287−94.Google Scholar
Muffly, LS, Boulukos, M, Swanson, K, Kocherginsky, M, Cerro, PD, Schroeder, L, et al. Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients. Biol Blood Marrow Transplant. 2013;19(3):429–34.Google Scholar
Morris, CL, Siegel, E, Barlogie, B, Cottler-Fox, M, Lin, P, Fassas, A, et al. Mobilization of CD34+ cells in elderly patients (>/ = 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120(3):413–23.CrossRefGoogle ScholarPubMed
Micallef, IN, Stiff, PJ, Stadtmauer, EA, Bolwell, BJ, Nademanee, AP, Maziarz, RT, et al. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients >/ = 60 and <60 years of age with non-Hodgkin’s lymphoma or multiple myeloma. Am J Hematol. 2013;88(12):1017–23.Google Scholar
Jantunen, E, Kuittinen, T, Penttila, K, Lehtonen, P, Mahlamaki, E, Nousiainen, T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or = 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant. 2006;37(10):917–22.CrossRefGoogle ScholarPubMed
Lenhoff, S, Hjorth, M, Westin, J, Brinch, L, Backstrom, B, Carlson, K, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol. 2006;133(4):389–96.Google Scholar
Kumar, SK, Dingli, D, Lacy, MQ, Dispenzieri, A, Hayman, SR, Buadi, FK, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol. 2008;83(8):614–7.Google Scholar
El-Cheikh, J, Kfoury, E, Calmels, B, Lemarie, C, Stoppa, AM, Bouabdallah, R, et al. Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2011;4(1):30–6.Google Scholar
Bashir, Q, Shah, N, Parmar, S, Wei, W, Rondon, G, Weber, DM, et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged >/ = 70 years with multiple myeloma. Leuk Lymphoma. 2012;53(1):118–22.CrossRefGoogle ScholarPubMed
Offidani, M, Leoni, P, Corvatta, L, Polloni, C, Gentili, S, Savini, A, et al. ThaDD plus high-dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. Eur J Haematol. 2010;84(6):474–83.Google Scholar
Facon, T, Mary, JY, Hulin, C, Benboubker, L, Attal, M, Pegourie, B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209–18.Google Scholar
Jantunen, E, Canals, C, Rambaldi, A, Ossenkoppele, G, Allione, B, Blaise, D, et al. Autologous stem cell transplantation in elderly patients (> or = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93(12):1837–42.Google Scholar
Lazarus, HM, Carreras, J, Boudreau, C, Loberiza, FR Jr., Armitage, JO, Bolwell, BJ, et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008;14(12):1323–33.Google Scholar
Wildes, TM, Augustin, KM, Sempek, D, Zhang, QJ, Vij, R, Dipersio, JF, et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(7):840–6.CrossRefGoogle Scholar
Jantunen, E, Canals, C, Attal, M, Thomson, K, Milpied, N, Buzyn, A, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23(1):166–71.Google Scholar
Elstrom, RL, Martin, P, Hurtado Rua, S, Shore, TB, Furman, RR, Ruan, J, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012;87(4):433–5.Google Scholar
Andorsky, DJ, Cohen, M, Naeim, A, Pinter-Brown, L. Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant. 2011;46(9):1219–25.Google Scholar
Pasquini, M, Logan, B, Ho, V, McCarthy, P Jr., Cooke, K, Rizzo, J, et al. Comorbidity Index (CI) in autologous hematopoietic cell transplantation (HCT) for malignant diseases: validation of the HCT-CI. Blood. 2012:Abstract 814.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×